Interestingly, CD8+/Treg ratios have been verified to increase upon combination checkpoint therapy in melanoma, improving survival in melanoma [67], and the CD8+/Treg ratio is associated to improved survival in ovarian [68] and gastrointestinal [69] cancers, among other tumor types. This evidence concerns the gene CD8A and melanoma.